C-116
Clomipramine-d3 hydrochloride solution
100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
别名:
Clomipramine-D3 hydrochloride solution
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C19D3H20ClN2 · HCl
化学文摘社编号:
分子量:
354.33
MDL number:
UNSPSC Code:
41116107
EC Number:
200-659-6
NACRES:
NA.24
grade
certified reference material
Quality Level
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
100 μg/mL in methanol (as free base)
technique(s)
gas chromatography (GC): suitable, liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
SMILES string
Clc1cc2c(cc1)CCc3c(cccc3)N2CCCN(C([2H])([2H])[2H])C.Cl
InChI
1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22;/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3;1H/i1D3;
InChI key
WIMWMKZEIBHDTH-NIIDSAIPSA-N
General description
Clomipramine is a tricyclic antidepressant used to many conditions from major depression and panic disorder to narcolepsy and obsessive compulsion disorder (OCD). This internal standard is is suitable for quantitation of Clomipramine levels in urine, serum, or plasma by LC/MS or GC/MS for applications in clinical toxicology, forensic analysis, isotope dilution methods, or pharmaceutical research.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Supply conditions do not apply to the regions and states of Brazil: North, Northeast, Mato Grosso do Sul, Mato Grosso, and Rio Grande do Sul.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
Luiza G Tunes et al.
ACS infectious diseases, 6(5), 1121-1139 (2020-04-15)
The drugs currently used to treat leishmaniases have limitations concerning cost, efficacy, and safety, making the search for new therapeutic approaches urgent. We found that the gold(I)-derived complexes were active against L. infantum and L. braziliensis intracellular amastigotes with IC50 values ranging
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| C-116-1ML | 04061833449660 |
| CRMUCFGO1-250ML | 04061838188731 |
| THSD2141-1EA | 04061834000471 |
| THSD8142-1EA | 04061834000686 |
| THSD1144-1EA | 04061834000273 |
| THSD6145-1EA | 04061834000662 |
| THSD2145-1EA | 04061834000532 |
| THSD1143-1EA | 04061834000259 |
| THSD1141-1EA | 04061834000211 |
| THSD1041-1EA | 04061834000181 |
| THSD1145-3EA | 04061834000297 |